More than 90% of cases are due to a deficiency of 21-hydroxylase enzymes required for the conversion of 170H-progesterone to 11-deoxycortisol and of progesterone to 11-deoxycorticosterone. The inheritance is autosomal recessive and the monogenic trait is closely linked to the HLA locus on chromosome 6.2 A further 5% of cases are associated with a deficiency of the 11i-hydroxylase enzyme involved in the terminal steps of cortisol and aldosterone biosynthesis. The clinical hallmark of both enzyme defects is virilisation consequent upon increased adrenocorticotrophic hormone secretion causing excess adrenal androgen production. The remaining enzyme defects causing congenital adrenal hyperplasia are very rare and their management is not discussed. ,
Clinical presentation
Fetal adrenal steroidogenesis is established in early gestation so that a female fetus with congenital adrenal hyperplasia invariably has virilised external genitalia at birth. The degree of virilisation can range from mild isolated clitoromegaly or partial labial fusion to complete fusion of the labioscrotal folds ('scrotalised' labia) and pronounced clitoromegaly with a phallic urethra. The latter variant may masquerade as a cryptorchid 'male' with or without hypospadias. Treatment in congenital adrenal hyperplasia should aim to ensure normal growth in infancy and childhood, the development of puberty at the appropriate age and later, the acquisition of adult reproductive potential. This goal needs to be achieved using the minimum amount of glucocorticoid required to suppress excess androgen production. There is a delicate balance to strike between the prevention of androgen induced rapid growth with advanced skeletal maturation on the one hand and the inhibition of normal growth from excessive glucocorticoid replacement on the other.
Several glucocorticoid preparations have been tried as regular replacement treatment in congenital adrenal hyperplasia. Their relative potencies in Clinical parameters of control in congenital adrenal hyperplasia include measurement of growth velocity and skeletal maturation (bone age), signs of hypercortisolism (striae, weight gain, hypertension), and noting the pattern of menses in postpubertal women. These are essential to monitor regularly but the parameters are insensitive indicators of control in the short term and are of necessity retrospective. Assessment of skeletal maturity is unreliable during infancy at a time when satisfactory control is essential if normal growth is to be sustained throughout childhood and adolescence. The outcome for adult height in the first generation of patients treated regularly with glucocorticoid replacement has generally been unsatisfactory. 18 19 Irregular menses and infertility in both sexes have been additional problems.
Several steroid parameters have been used to monitor adequacy of treatment in congenital adrenal hyperplasia. Urinary 17-oxosteroid andpregnanetriol excretion is an insensitive index of control and is seldom used now. Single random determinations of plasma 170H-progesterone concentrations are difficult to interprete because of the combined influences of stress, an intrinsic circadian rhythm, and the timing of previous glucocorticoid medication on adrenal steroid hormone concentrations. A very high early morning concentration of 170H-progesterone can fall to normal values by late afternoon even in a poorly controlled patient. The interpretation of a single estimation of 170H-progesterone would clearly be quite different for samples collected in morning and afternoon clinics. The problem can be circumvented by the use of daily profiles of 170H-progesterone. The availability to measure this steroid in filter paper blood spots and saliva makes it possible for frequent, serial Management of congenital adrenal hyperplasia 1403 samples to be collected at home by patients with congenital adrenal hyperplasia of all ages.
Pictorial nomograms of 170H-progesterone rhythms have recently been constructed to interpret the daily profiles of blood spot and saliva 170H-progesterone measurements in individual patients with congenital adrenal hyperplasia.20 The magnitude of the circadian rhythm is an important index of control. The disappearance of the rhythm is an early sign of overtreatment. Table 4 
Newborn screening
The incidence of congenital adrenal hyperplasia based on several pilot newborn screening programmes is about 1 in 10 000 white births, but as high as 1 in 230 among the Yupik Eskimos. Measurement of 170H-progesterone in a filter paper blood spot sample is simple to perform. However, false positive results are sometimes observed in sick preterm infants. Table 5 lists the problems which are 
